Tocilizumab, a novel monoclonal antibody targeting IL-6 signalling, significantly reduces disease activity in patients with rheumatoid arthritis

被引：0
|
作者：
Smolen, J. [1 ]
Beaulieu, A. [2 ]
Rubbert-Roth, A. [3 ]
Alecock, E. [4 ]
Alten, R. [5 ]
Woodworth, T. [4 ]
机构：
[1] Univ Clin Internal Med, Clin Dept Pheumatol, Vienna, Austria
[2] Univ Laval, Fac Med, Quebec City, PQ G1K 7P4, Canada
[3] Univ Cologne, Med Clin 1, Cologne, Germany
[4] Roche Prod Ltd, Welwyn, SK, Canada
[5] Charite Univ Med Berlin, Schlosspk Clin, Dept Internal Med 2, D-13353 Berlin, Germany
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2007年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：87 / 88
页数：2
相关论文
共 50 条
  • [1] Tocilizumab, a novel monoclonal antibody targeting il-6 signalling, significantly improves quality of life in patients with rheumatoid arthritis
    Allen, R.
    Ramos-Remus, C.
    Rovensky, J.
    Lucero, M.
    Woodworth, T.
    Smolens, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 428 - 428
  • [2] Targeting the IL-6 receptor with the monoclonal antibody tocilizumab significantly improves quality of life in patients with rheumatoid arthritis
    Smolen, J.
    Atkins, C.
    Rovensky, J.
    Ramos-Remus, C.
    Lucero, M.
    Woodworth, T.
    Alten, R.
    JOURNAL OF RHEUMATOLOGY, 2008, 35 (06) : 1181 - 1182
  • [3] Targeted inhibition of the IL-6 receptor with tocilizumab effectively reduces disease activity in patients with rheumatoid arthritis
    Beaulieu, Andre D.
    Zummer, Michel
    Rubbert-Roth, Andrea
    Woodworth, Thasia
    Alecock, Emma
    Alien, Rieke
    Smolen, Josef
    JOURNAL OF RHEUMATOLOGY, 2008, 35 (06) : 1186 - 1186
  • [4] EFFECT OF TOCILIZUMAB THERAPY ON IL-6 SIGNALLING PATHWAY IN EARLY RHEUMATOID ARTHRITIS PATIENTS
    Ouboussad, Lylia
    Wong, Chi
    Hunt, Laura
    Emery, Paul
    McDermott, Michael F.
    Aslam, Aamir
    Buch, Maya H.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : A40 - A40
  • [5] IL-6 receptor inhibition with tocilizumab reduces disease activity in patients with rheumatoid arthritis with inadequate response to a range of DMARDs: The TOWARD study
    Genovese, M.
    Brown, J. P.
    Mckay, J.
    Nasonov, E.
    Mysler, E.
    da Silva, N.
    Alecock, E.
    Gomez-Reino, J.
    JOURNAL OF RHEUMATOLOGY, 2008, 35 (06) : 1187 - 1187
  • [6] IL-6 receptor inhibition with tocilizumab reduces disease activity in patients with rheumatoid arthritis with inadequate response to a range of DMARDs: The TOWARD study
    Genovese, M.
    McKay, J.
    Nasonov, E.
    Myster, E.
    da Silva, N.
    Alecock, E.
    Woodworth, T.
    Gomez-Reino, J.
    ARTHRITIS AND RHEUMATISM, 2007, 56 (12): : 4309 - 4310
  • [7] The Combination of IL-6 and IL-6 Receptor Levels As a Biomarker of Response to Tocilizumab in Rheumatoid Arthritis Patients
    Diaz-Torne, Cesar
    Ortiz, Maria A.
    Moya, Patricia
    Victoria Hernandez, M.
    Reina, Delia
    Castellvi, Ivan
    Jose De Agustin, Juan
    De La Fuente, Diana
    Corominas, Hector
    Sanmarti, Raimon
    De Llobet Zubiaga, Josep Maria
    Vidal, Silvia
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [8] Interleukin 6 (IL-6) signalling in rheumatoid arthritis
    Carty, SM
    Nowell, MA
    Goodfellow, RM
    Topley, N
    Jones, SA
    Williams, BD
    Williams, AS
    RHEUMATOLOGY, 2005, 44 : I38 - I38
  • [9] Tocilizumab - A humanized anti-IL-6 receptor monoclonal antibody for the treatment of rheumatoid arthritis
    Schlesselman, Lauren S.
    Hussey, Aaron P.
    FORMULARY, 2008, 43 (08) : 272 - 279
  • [10] Novel therapy for Crohn's disease targeting IL-6 signalling
    Ito, H
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2004, 8 (04) : 287 - 294
12345